6 Presence and Impact of Possible Tardive Dyskinesia in Patients Prescribed Antipsychotics: Results from the RE-KINECT Study
ObjectiveTardive dyskinesia (TD) is a hyperkinetic movement disorder associated with antipsychotic treatment. RE KINECT (NCT03062033), a real-world study of outpatients prescribed antipsychotics, was designed to identify the presence of possible TD and characterize the impact of involuntary movement...
Gespeichert in:
| Veröffentlicht in: | CNS spectrums 2019-02, Vol.24 (1), p.176-177 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 177 |
|---|---|
| container_issue | 1 |
| container_start_page | 176 |
| container_title | CNS spectrums |
| container_volume | 24 |
| creator | Cutler, Andrew J. Caroff, Stanley N. Tanner, Caroline M. Shalhoub, Huda Lenderking, William R. Chen, Jun Yeomans, Karen Anthony, Ericha Yonan, Chuck |
| description | ObjectiveTardive dyskinesia (TD) is a hyperkinetic movement disorder associated with antipsychotic treatment. RE KINECT (NCT03062033), a real-world study of outpatients prescribed antipsychotics, was designed to identify the presence of possible TD and characterize the impact of involuntary movements on functioning and quality of life. Data from RE-KINECT were used to compare the impact of possible TD in patients with schizophrenia/schizoaffective disorder [SZD] versus mood/other psychiatric disorders [Mood].MethodsAdults with ≥3months of lifetime exposure to antipsychotics and ≥1 psychiatric disorder were recruited. The presence of possible TD was based on clinicians’ observation of involuntary movements in 4 body regions (head, trunk, upper extremities, and lower extremities). Baseline outcomes included demographics, medication history, location/severity of abnormal movements, impact of abnormal movements on daily activities, the Sheehan Disability Scale (SDS), and the EuroQoL 5-Dimensional questionnaire (EQ-5D-5L).ResultsOf 204 patients with clinician-confirmed possible TD, 111 (54.4%) had a SZD diagnosis and 93 (45.6%) had a mood/other psychiatric diagnosis. Significant differences found between groups (Mood vs SZD) included: mean age (56.9 vs 52.7 years; P=0.0263); male sex (33.3% vs 62.2%; P |
| doi_str_mv | 10.1017/S109285291900004X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2788151563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2788151563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c113x-cb27c09afd1680742e9ca674734acfe67c4a2e280b1f97b1bae6395c65dee72f3</originalsourceid><addsrcrecordid>eNplkM1OwzAQhC0EEqXwANwscQ74J7ETblUpUFFB1RaJW-Q4a9WlTYLtICLx8KSUG3uZw3w7qx2ELim5poTKmyUlGUsTltGM9BO_HaEBoyKJREKyYzTY29HeP0Vn3m96gsuUD9C3wHMHHioNWFUlnu4apQOuDZ7X3ttiC3ilXGk_Ad91_t1W4K3CtsJzFSxUwf-ua2cLKPGoCrbxnV7XwWp_ixfg222PGFfvcFgDXkyip-nzZLzCy9CW3Tk6MWrr4eJPh-j1frIaP0azl4fpeDSLNKX8K9IFk5pkypRUpETGDDKthIwlj5U2IKSOFQOWkoKaTBa0UCB4lmiRlACSGT5EV4fcxtUfLfiQb-rWVf3JnMk0pQlNBO8peqC06193YPLG2Z1yXU5Jvi85_1cy_wEt8m-8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2788151563</pqid></control><display><type>article</type><title>6 Presence and Impact of Possible Tardive Dyskinesia in Patients Prescribed Antipsychotics: Results from the RE-KINECT Study</title><source>Cambridge University Press Journals Complete</source><creator>Cutler, Andrew J. ; Caroff, Stanley N. ; Tanner, Caroline M. ; Shalhoub, Huda ; Lenderking, William R. ; Chen, Jun ; Yeomans, Karen ; Anthony, Ericha ; Yonan, Chuck</creator><creatorcontrib>Cutler, Andrew J. ; Caroff, Stanley N. ; Tanner, Caroline M. ; Shalhoub, Huda ; Lenderking, William R. ; Chen, Jun ; Yeomans, Karen ; Anthony, Ericha ; Yonan, Chuck</creatorcontrib><description>ObjectiveTardive dyskinesia (TD) is a hyperkinetic movement disorder associated with antipsychotic treatment. RE KINECT (NCT03062033), a real-world study of outpatients prescribed antipsychotics, was designed to identify the presence of possible TD and characterize the impact of involuntary movements on functioning and quality of life. Data from RE-KINECT were used to compare the impact of possible TD in patients with schizophrenia/schizoaffective disorder [SZD] versus mood/other psychiatric disorders [Mood].MethodsAdults with ≥3months of lifetime exposure to antipsychotics and ≥1 psychiatric disorder were recruited. The presence of possible TD was based on clinicians’ observation of involuntary movements in 4 body regions (head, trunk, upper extremities, and lower extremities). Baseline outcomes included demographics, medication history, location/severity of abnormal movements, impact of abnormal movements on daily activities, the Sheehan Disability Scale (SDS), and the EuroQoL 5-Dimensional questionnaire (EQ-5D-5L).ResultsOf 204 patients with clinician-confirmed possible TD, 111 (54.4%) had a SZD diagnosis and 93 (45.6%) had a mood/other psychiatric diagnosis. Significant differences found between groups (Mood vs SZD) included: mean age (56.9 vs 52.7 years; P=0.0263); male sex (33.3% vs 62.2%; P<0.0001); African-American race (7.5% vs 26.1%; P=0.0005); mean lifetime exposure to antipsychotics (9.5 vs 19.5 years; P<0.0001); and percentage of patients currently taking ≥2 psychiatric medications (93.5% vs 79.3%; P=0.0093). Based on clinician observation, there were no significant differences between diagnosis groups in the number of body regions impacted by abnormal movements, maximum severity score across all 4 regions, or patient awareness of possible TD. Over 30% of patients in both groups reported that involuntary movements had “some” or “a lot” of impact on their ability to continue usual activities, be productive, and socialize. No significant differences between the diagnosis groups (Mood vs SZD) were found for mean SDS total score (12.8 vs 10.8), SDS domain scores (work/school [4.1 vs 4.2], social life [4.3 vs 3.7], family life [4.1 vs 3.5]), EQ-5D-5L utility score (0.68 vs 0.74), or EQ-5D-5L health state VAS (64.8 vs 68.5).ConclusionsIn this cohort of outpatients with possible TD, those with Mood disorders were more likely to be older, female, and white than patients with SZD. The ability to function and quality of life were equally impaired in both groups. Further studies on the impact of TD are needed.Funding Acknowledgements: Neurocrine Biosciences, Inc.</description><identifier>ISSN: 1092-8529</identifier><identifier>EISSN: 2165-6509</identifier><identifier>DOI: 10.1017/S109285291900004X</identifier><language>eng</language><publisher>New York: Cambridge University Press</publisher><subject>Antipsychotics ; Dyskinesia ; Mental disorders ; Psychotropic drugs ; Quality of life ; Schizoaffective disorder</subject><ispartof>CNS spectrums, 2019-02, Vol.24 (1), p.176-177</ispartof><rights>Cambridge University Press 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Cutler, Andrew J.</creatorcontrib><creatorcontrib>Caroff, Stanley N.</creatorcontrib><creatorcontrib>Tanner, Caroline M.</creatorcontrib><creatorcontrib>Shalhoub, Huda</creatorcontrib><creatorcontrib>Lenderking, William R.</creatorcontrib><creatorcontrib>Chen, Jun</creatorcontrib><creatorcontrib>Yeomans, Karen</creatorcontrib><creatorcontrib>Anthony, Ericha</creatorcontrib><creatorcontrib>Yonan, Chuck</creatorcontrib><title>6 Presence and Impact of Possible Tardive Dyskinesia in Patients Prescribed Antipsychotics: Results from the RE-KINECT Study</title><title>CNS spectrums</title><description>ObjectiveTardive dyskinesia (TD) is a hyperkinetic movement disorder associated with antipsychotic treatment. RE KINECT (NCT03062033), a real-world study of outpatients prescribed antipsychotics, was designed to identify the presence of possible TD and characterize the impact of involuntary movements on functioning and quality of life. Data from RE-KINECT were used to compare the impact of possible TD in patients with schizophrenia/schizoaffective disorder [SZD] versus mood/other psychiatric disorders [Mood].MethodsAdults with ≥3months of lifetime exposure to antipsychotics and ≥1 psychiatric disorder were recruited. The presence of possible TD was based on clinicians’ observation of involuntary movements in 4 body regions (head, trunk, upper extremities, and lower extremities). Baseline outcomes included demographics, medication history, location/severity of abnormal movements, impact of abnormal movements on daily activities, the Sheehan Disability Scale (SDS), and the EuroQoL 5-Dimensional questionnaire (EQ-5D-5L).ResultsOf 204 patients with clinician-confirmed possible TD, 111 (54.4%) had a SZD diagnosis and 93 (45.6%) had a mood/other psychiatric diagnosis. Significant differences found between groups (Mood vs SZD) included: mean age (56.9 vs 52.7 years; P=0.0263); male sex (33.3% vs 62.2%; P<0.0001); African-American race (7.5% vs 26.1%; P=0.0005); mean lifetime exposure to antipsychotics (9.5 vs 19.5 years; P<0.0001); and percentage of patients currently taking ≥2 psychiatric medications (93.5% vs 79.3%; P=0.0093). Based on clinician observation, there were no significant differences between diagnosis groups in the number of body regions impacted by abnormal movements, maximum severity score across all 4 regions, or patient awareness of possible TD. Over 30% of patients in both groups reported that involuntary movements had “some” or “a lot” of impact on their ability to continue usual activities, be productive, and socialize. No significant differences between the diagnosis groups (Mood vs SZD) were found for mean SDS total score (12.8 vs 10.8), SDS domain scores (work/school [4.1 vs 4.2], social life [4.3 vs 3.7], family life [4.1 vs 3.5]), EQ-5D-5L utility score (0.68 vs 0.74), or EQ-5D-5L health state VAS (64.8 vs 68.5).ConclusionsIn this cohort of outpatients with possible TD, those with Mood disorders were more likely to be older, female, and white than patients with SZD. The ability to function and quality of life were equally impaired in both groups. Further studies on the impact of TD are needed.Funding Acknowledgements: Neurocrine Biosciences, Inc.</description><subject>Antipsychotics</subject><subject>Dyskinesia</subject><subject>Mental disorders</subject><subject>Psychotropic drugs</subject><subject>Quality of life</subject><subject>Schizoaffective disorder</subject><issn>1092-8529</issn><issn>2165-6509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNplkM1OwzAQhC0EEqXwANwscQ74J7ETblUpUFFB1RaJW-Q4a9WlTYLtICLx8KSUG3uZw3w7qx2ELim5poTKmyUlGUsTltGM9BO_HaEBoyKJREKyYzTY29HeP0Vn3m96gsuUD9C3wHMHHioNWFUlnu4apQOuDZ7X3ttiC3ilXGk_Ad91_t1W4K3CtsJzFSxUwf-ua2cLKPGoCrbxnV7XwWp_ixfg222PGFfvcFgDXkyip-nzZLzCy9CW3Tk6MWrr4eJPh-j1frIaP0azl4fpeDSLNKX8K9IFk5pkypRUpETGDDKthIwlj5U2IKSOFQOWkoKaTBa0UCB4lmiRlACSGT5EV4fcxtUfLfiQb-rWVf3JnMk0pQlNBO8peqC06193YPLG2Z1yXU5Jvi85_1cy_wEt8m-8</recordid><startdate>201902</startdate><enddate>201902</enddate><creator>Cutler, Andrew J.</creator><creator>Caroff, Stanley N.</creator><creator>Tanner, Caroline M.</creator><creator>Shalhoub, Huda</creator><creator>Lenderking, William R.</creator><creator>Chen, Jun</creator><creator>Yeomans, Karen</creator><creator>Anthony, Ericha</creator><creator>Yonan, Chuck</creator><general>Cambridge University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>201902</creationdate><title>6 Presence and Impact of Possible Tardive Dyskinesia in Patients Prescribed Antipsychotics: Results from the RE-KINECT Study</title><author>Cutler, Andrew J. ; Caroff, Stanley N. ; Tanner, Caroline M. ; Shalhoub, Huda ; Lenderking, William R. ; Chen, Jun ; Yeomans, Karen ; Anthony, Ericha ; Yonan, Chuck</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c113x-cb27c09afd1680742e9ca674734acfe67c4a2e280b1f97b1bae6395c65dee72f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antipsychotics</topic><topic>Dyskinesia</topic><topic>Mental disorders</topic><topic>Psychotropic drugs</topic><topic>Quality of life</topic><topic>Schizoaffective disorder</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cutler, Andrew J.</creatorcontrib><creatorcontrib>Caroff, Stanley N.</creatorcontrib><creatorcontrib>Tanner, Caroline M.</creatorcontrib><creatorcontrib>Shalhoub, Huda</creatorcontrib><creatorcontrib>Lenderking, William R.</creatorcontrib><creatorcontrib>Chen, Jun</creatorcontrib><creatorcontrib>Yeomans, Karen</creatorcontrib><creatorcontrib>Anthony, Ericha</creatorcontrib><creatorcontrib>Yonan, Chuck</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Psychology</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>CNS spectrums</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cutler, Andrew J.</au><au>Caroff, Stanley N.</au><au>Tanner, Caroline M.</au><au>Shalhoub, Huda</au><au>Lenderking, William R.</au><au>Chen, Jun</au><au>Yeomans, Karen</au><au>Anthony, Ericha</au><au>Yonan, Chuck</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>6 Presence and Impact of Possible Tardive Dyskinesia in Patients Prescribed Antipsychotics: Results from the RE-KINECT Study</atitle><jtitle>CNS spectrums</jtitle><date>2019-02</date><risdate>2019</risdate><volume>24</volume><issue>1</issue><spage>176</spage><epage>177</epage><pages>176-177</pages><issn>1092-8529</issn><eissn>2165-6509</eissn><abstract>ObjectiveTardive dyskinesia (TD) is a hyperkinetic movement disorder associated with antipsychotic treatment. RE KINECT (NCT03062033), a real-world study of outpatients prescribed antipsychotics, was designed to identify the presence of possible TD and characterize the impact of involuntary movements on functioning and quality of life. Data from RE-KINECT were used to compare the impact of possible TD in patients with schizophrenia/schizoaffective disorder [SZD] versus mood/other psychiatric disorders [Mood].MethodsAdults with ≥3months of lifetime exposure to antipsychotics and ≥1 psychiatric disorder were recruited. The presence of possible TD was based on clinicians’ observation of involuntary movements in 4 body regions (head, trunk, upper extremities, and lower extremities). Baseline outcomes included demographics, medication history, location/severity of abnormal movements, impact of abnormal movements on daily activities, the Sheehan Disability Scale (SDS), and the EuroQoL 5-Dimensional questionnaire (EQ-5D-5L).ResultsOf 204 patients with clinician-confirmed possible TD, 111 (54.4%) had a SZD diagnosis and 93 (45.6%) had a mood/other psychiatric diagnosis. Significant differences found between groups (Mood vs SZD) included: mean age (56.9 vs 52.7 years; P=0.0263); male sex (33.3% vs 62.2%; P<0.0001); African-American race (7.5% vs 26.1%; P=0.0005); mean lifetime exposure to antipsychotics (9.5 vs 19.5 years; P<0.0001); and percentage of patients currently taking ≥2 psychiatric medications (93.5% vs 79.3%; P=0.0093). Based on clinician observation, there were no significant differences between diagnosis groups in the number of body regions impacted by abnormal movements, maximum severity score across all 4 regions, or patient awareness of possible TD. Over 30% of patients in both groups reported that involuntary movements had “some” or “a lot” of impact on their ability to continue usual activities, be productive, and socialize. No significant differences between the diagnosis groups (Mood vs SZD) were found for mean SDS total score (12.8 vs 10.8), SDS domain scores (work/school [4.1 vs 4.2], social life [4.3 vs 3.7], family life [4.1 vs 3.5]), EQ-5D-5L utility score (0.68 vs 0.74), or EQ-5D-5L health state VAS (64.8 vs 68.5).ConclusionsIn this cohort of outpatients with possible TD, those with Mood disorders were more likely to be older, female, and white than patients with SZD. The ability to function and quality of life were equally impaired in both groups. Further studies on the impact of TD are needed.Funding Acknowledgements: Neurocrine Biosciences, Inc.</abstract><cop>New York</cop><pub>Cambridge University Press</pub><doi>10.1017/S109285291900004X</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1092-8529 |
| ispartof | CNS spectrums, 2019-02, Vol.24 (1), p.176-177 |
| issn | 1092-8529 2165-6509 |
| language | eng |
| recordid | cdi_proquest_journals_2788151563 |
| source | Cambridge University Press Journals Complete |
| subjects | Antipsychotics Dyskinesia Mental disorders Psychotropic drugs Quality of life Schizoaffective disorder |
| title | 6 Presence and Impact of Possible Tardive Dyskinesia in Patients Prescribed Antipsychotics: Results from the RE-KINECT Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T08%3A04%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=6%20Presence%20and%20Impact%20of%20Possible%20Tardive%20Dyskinesia%20in%20Patients%20Prescribed%20Antipsychotics:%20Results%20from%20the%20RE-KINECT%20Study&rft.jtitle=CNS%20spectrums&rft.au=Cutler,%20Andrew%20J.&rft.date=2019-02&rft.volume=24&rft.issue=1&rft.spage=176&rft.epage=177&rft.pages=176-177&rft.issn=1092-8529&rft.eissn=2165-6509&rft_id=info:doi/10.1017/S109285291900004X&rft_dat=%3Cproquest_cross%3E2788151563%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2788151563&rft_id=info:pmid/&rfr_iscdi=true |